ICU Medical Inc. (NASDAQ:ICUI) Director Richard Md Sherman sold 1,500 shares of the firm’s stock in a transaction dated Thursday, October 6th. The shares were sold at an average price of $140.60, for a total transaction of $210,900.00. Following the transaction, the director now directly owns 70,699 shares in the company, valued at approximately $9,940,279.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Richard Md Sherman also recently made the following trade(s):

  • On Monday, September 19th, Richard Md Sherman sold 3,000 shares of ICU Medical stock. The shares were sold at an average price of $122.51, for a total transaction of $367,530.00.

ICU Medical Inc. (NASDAQ:ICUI) opened at 149.65 on Friday. The stock has a 50 day moving average of $126.14 and a 200-day moving average of $112.44. ICU Medical Inc. has a 12 month low of $85.56 and a 12 month high of $150.37. The stock has a market cap of $2.41 billion, a P/E ratio of 44.57 and a beta of 0.37.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Monday, August 8th. The company reported $1.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.10. ICU Medical had a net margin of 14.94% and a return on equity of 10.33%. The firm earned $96.70 million during the quarter, compared to analyst estimates of $89.66 million. During the same quarter in the prior year, the firm posted $0.97 earnings per share. ICU Medical’s quarterly revenue was up 15.4% on a year-over-year basis. On average, equities analysts forecast that ICU Medical Inc. will post $4.54 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

A number of research analysts have commented on the stock. Piper Jaffray Cos. reissued a “neutral” rating and set a $119.00 target price (up previously from $115.00) on shares of ICU Medical in a research report on Thursday, August 11th. Zacks Investment Research raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $140.00 target price on the stock in a research report on Friday, August 12th.

Several large investors have recently made changes to their positions in the stock. Virginia Retirement System purchased a new stake in shares of ICU Medical during the first quarter worth about $333,000. Teachers Advisors Inc. raised its position in shares of ICU Medical by 13.3% in the first quarter. Teachers Advisors Inc. now owns 202,753 shares of the company’s stock valued at $21,107,000 after buying an additional 23,812 shares during the period. JPMorgan Chase & Co. raised its position in shares of ICU Medical by 63.5% in the first quarter. JPMorgan Chase & Co. now owns 185,078 shares of the company’s stock valued at $19,267,000 after buying an additional 71,891 shares during the period. Menta Capital LLC raised its position in shares of ICU Medical by 157.1% in the first quarter. Menta Capital LLC now owns 5,400 shares of the company’s stock valued at $562,000 after buying an additional 3,300 shares during the period. Finally, M&T Bank Corp raised its position in shares of ICU Medical by 3.3% in the first quarter. M&T Bank Corp now owns 2,117 shares of the company’s stock valued at $220,000 after buying an additional 67 shares during the period. 89.50% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

5 Day Chart for NASDAQ:ICUI

Receive News & Stock Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related stocks with our FREE daily email newsletter.